日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma

免疫细胞因子 Simlukafusp Alfa (FAP-IL2v) 联合 Pembrolizumab 治疗晚期和/或转移性黑色素瘤的 Ib 期研究

Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V Long, Miguel F Sanmamed, Anna Spreafico, Elizabeth Buchbinder, Mario Sznol, Hans Prenen, Alexander Fedenko, Mohammed Milhem, Ana Maria Arance Fernandez, Jean-Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, 

Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

转化生长因子-β (TGFβ) 抑制剂 SAR439459 作为单一疗法和与 cemiplimab 联合治疗晚期实体肿瘤患者的 I 期临床研究的生物标志物和药效学活性

Debbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, Matteo Simonelli, Bernard Doger, Ivan Borbath, Marcus O Butler, Tina Cheng, Patricia Martin Romano, Elvire Pons-Tostivint, Massimo Di Nicola, Giuseppe Curigliano, Min-Hee Ryu, Alejo Rodriguez-Vida, Dirk Schadendorf, Elena Garralda, Giovanni Abbade

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

纳武利尤单抗和瑞拉利单抗治疗接受过抗程序性死亡受体-1/程序性死亡配体1治疗后病情进展的晚期黑色素瘤患者:I/IIa期RELATIVITY-020试验结果

Paolo Antonio Ascierto,Evan J Lipson,Reinhard Dummer,James Larkin,Georgina V Long,Rachel E Sanborn,Vanna Chiarion-Sileni,Brigitte Dréno,Stéphane Dalle,Dirk Schadendorf,Margaret K Callahan,Marta Nyakas,Victoria Atkinson,Carlos Alberto Gomez-Roca,Naoya Yamazaki,Hussein A Tawbi,Naomey Sarkis,Deepti Warad,Sonia Dolfi,Priyam Mitra,Satyendra Suryawanshi,Jean-Jacques Grob

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

达拉非尼联合曲美替尼治疗 BRAF 突变型黑色素瘤脑转移患者的临床特征及疗效和生物标志物分析

James S Wilmott, Hussein Tawbi, Johnathan A Engh, Nduka M Amankulor, Brindha Shivalingam, Hiya Banerjee, Ismael A Vergara, Hansol Lee, Peter A Johansson, Peter M Ferguson, Philippe Saiag, Caroline Robert, Jean-Jacques Grob, Lisa H Butterfield, Richard A Scolyer, John M Kirkwood #, Georgina V Long #,

Adrenomedullin Secreted by Melanoma Cells Promotes Melanoma Tumor Growth through Angiogenesis and Lymphangiogenesis

黑色素瘤细胞分泌的肾上腺髓质素通过血管生成和淋巴管生成促进黑色素瘤肿瘤生长

Zohra Benyahia, Caroline Gaudy-Marqueste, Caroline Berenguer-Daizé, Norhimane Chabane, Nadège Dussault, Mylène Cayol, Christine Vellutini, Amina Djemli, Isabelle Nanni, Nathalie Beaufils, Kamel Mabrouk, Jean-Jacques Grob, L'Houcine Ouafik

Identification of an Immature Subset of PMN-MDSC Correlated to Response to Checkpoint Inhibitor Therapy in Patients with Metastatic Melanoma

鉴定出与转移性黑色素瘤患者检查点抑制剂治疗反应相关的 PMN-MDSC 未成熟亚群

Françoise Gondois-Rey, Magali Paul, Florence Alcaraz, Sarah Bourass, Jilliana Monnier, Nausicaa Malissen, Jean-Jacques Grob, Annika M Bruger, Pierre Van Der Bruggen, Caroline Gaudy-Marqueste, Daniel Olive

HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma

HVEM 的表达范围比 PD-L1 更广,是黑色素瘤的负面预后标志物和潜在治疗靶点

Nausicaa Malissen, Nicolas Macagno, Samuel Granjeaud, Clémence Granier, Vincent Moutardier, Caroline Gaudy-Marqueste, Nadia Habel, Marion Mandavit, Bernard Guillot, Christine Pasero, Eric Tartour, Robert Ballotti, Jean-Jacques Grob, Daniel Olive

LBR mutation and nuclear envelope defects in a patient affected with Reynolds syndrome

雷诺兹综合征患者的 LBR 突变和核膜缺陷

Caroline Gaudy-Marqueste, Patrice Roll, Vera Esteves-Vieira, Pierre-Jean Weiller, Jean Jacques Grob, Pierre Cau, Nicolas Lévy, Annachiara De Sandre-Giovannoli